Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | VCP | P55072 | 2/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568301 | 0.85 | CYP19A1 (0.53) | CYP19A1VCPPKN2CYP11B1HPGDS | |
| SCHEMBL4568282 | 0.84 | NPC1 (0.47) | CYP19A1VCPNPY5RKDM4ENPC1 | |
| SCHEMBL4568295 | 0.79 | CYP19A1 (0.58) | CYP19A1CYP11B1NPY5RCYP11B2TDO2 | |
| SCHEMBL4568273 | 0.79 | CYP19A1 (0.58) | CYP19A1CYP11B1NPY5RCYP11B2TDO2 | |
| SCHEMBL4568284 | 0.79 | CYP1A1 (0.43) | VCPKDM4ESMN1; SMN2 | |
| SCHEMBL4568281 | 0.78 | CYP19A1 (0.61) | CYP19A1VCPPKN2HPGDSNPY5R | |
| SCHEMBL4568294 | 0.76 | CYP19A1 (0.58) | CYP19A1VCPCYP11B1NPY5RCYP11B2 | |
| SCHEMBL4568260 | 0.76 | CYP19A1 (0.55) | CYP19A1CYP11B1NPY5RCYP11B2KDM4E | |
| SCHEMBL4568285 | 0.74 | CDK5 (0.36) | VCPNPY5RMAPT | |
| SCHEMBL1606556 | 0.74 | CYP19A1 (0.68) | CYP19A1VCPCYP11B1HPGDSCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | CYP19A1 1262/4885VCP 4545/4885PKN2 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.